Synthesis and biological evaluation of immunoconjugates of adriamycin and a human IgM linked by poly[N5-(2-hydroxyethyl)-l-glutamine by Hoes, C.J.T. et al.




Synthesis and biological evaluation of immunoconjugates of
adriamycin and a human IgM linked by 
poly[NS-(2-hydroxyethyl)-L-glutamine] 
a C.J.T. Hoes a M. Ankon6 a, j. Grootoonk J. Feijen a,*, E. van der Struik b, 
b ~ A. van Doornmalen b, D. Pham b, A. de Man , A. van Ettekoven b, I. Schlachter b, 
P.J. Boon b, F. Kaspersen b, E.S. Bos b 
Department of Chemical Technology, University of Twente. P.O. Box 217, 7500 AE Enschede, The Netherlands 
b N. V. Organon, P.O. Box 20, 5340 BH Oss, The Netherlands 
Received 5 November 1993: accepted 18 August 1995 
Abstract 
The synthesis and purification of radiolabelled immunoconjugates, composed of a human IgM monoclonal antibody (IgM 
16.88) directed against an intracellular tumour-associated antigen, the drug carrier poly [NS-(2-hydroxyethyl)-L-glutamine] 
(PHEG) and the cytostatic drug adriamycin (ADR) are described. The immunoconjugates were constructed to allow selective 
release of ADR in the putatively acidic environment of the tumour through a novel acid-labile maleamic acid linker. The 
conjugate of PHEG and the acid-labile ADR derivative ffectively released ADR in cytotoxic amounts at a pH of 6.0 as judged 
from incubation in buffer and from inhibition of the growth of HT-29 colon tumour cells in vitro. Immunoconjugates were 
prepared by coupling of PHEG-ADR having a hydrolytically stable amide bond with J3q-labelled antibody through tbioether 
bond formation involving a single thiol group at the C-terminus of the polymer chain and maleimido groups introduced onto the 
* Corresponding author. 
Abbreviations: AcOSu,N-succinimidyl acetate; ADR, adriamycin; AEC, anion-exchange chromatography; ASI, active specific immunotherapy; 
BOC, tert-butox ycarbonyl ; (BOC) 20, di-tert-butyldicarbonate; BOC-AB, N-tert-butox ycarbonyl- 1,4-diaminobutane; BOC-OEA, N-tert-buto x-
ycarbonyl-2,2'-oxybis(ethylamine); CDI, N,N'-carbonyldiimidazole; CHC13, chloroform; CH2CIz, dichloromethane; CTA-I, colon tumour- 
associated antigen; Cys, cysteine; d. doublet; dd, double doublet; dt, double triplet; DAB, 3,3'-aminobenzidine; DMF. N,N'-dimethylformamide; 
DMSO, dimethylsulfoxide; DPn, number-average degree of polymerization; DPw, weight-average degree of polymerization; DSS, 4,4-dimethyl- 
4-silapentane sodium sulphonate; DTNB, 5,5'-dithiobis ( 2-nitrobenzoic a id) ;DTP, 4,4'-dithiodipyridine; DTT, dithiothreitol; e, molar absorb- 
ance coefficient; EEDQ, N-ethoxycarbonyl-2-ethoxy-l,2-dihydroquinoline; EIA, enzyme-linked immunoassay; Et20, diethyl ether; FABMS, 
fast atom bombardment mass spectrometry; FCS, fetal calf serum; GABA, y-aminobutyric a id; GMB, y-maleimidobutyryl; GMBS, N-(y- 
maleimidobutyryloxy)succinimide; HOAc, acetic acid; HONSu, N-hydroxysuccinimide; HPMA, N-(2-hydroxypropyl)methacrylamide; HP- 
SEC, high-performance size exclusion chromatography; HRP, horseradish peroxidase; LALLS, low-angle laser light scattering; m, multiplet; 
M,. number-average molecular weight; Mw, weight-average molecular weight; MRW, mean residue weight; MoAb, monoclonal ntibody: MSA, 
methanesulphonic acid; MTT, 3- (4.5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide; NAN,, sodium azide; NCA, N-carboxyanhydride; 
PBLG, poly( T-benzyl-L-glutamate); PBS, phosphate-buffered saline; PDT, 2-pyridyldithio; PGA, poly(Ol-L-glutamate) ; PHEG, poly[NS-(2 - 
hydroxyethyl)-L-glutamine]; PVDF, poly(vinylidene fluoride); q, quintet; s, singlet; SDS-PAGE, polyacrylamide gel electrophoresis in the 
presence of sodium dodecylsulphonate; TMS, tetramethylsilane; SATA, S-acetylthioacetyl; SEC, size exclusion chromatography; SMCC, 
succinimidyl 4- [ N-maleimidomethyl ] cyclohexane- I -carboxylate; sulfo-SMCC, sulfosuccinimidyl 4- [ N-maleimidomethyl ] cyclohexane- l-car- 
boxylate; TEA, triethylamine; TFA, trifluoroacetic acid; TLC. thin-layer chromatography; TMB, 3,3',5,5'-tetramethylbenzidine 
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antibody. The immunoreactivity of IgM-PHEG-ADR conjugate was almost fully preserved. Tumour uptake and biodistribution 
of ~251-1abelled PHEG-ADR and of ~3q-labelled IgM-PHEG-ADR, which was co-administered with ~H-labelled IgM 16.88, in 
nude mice carrying MRI-W207 human ovarian tumour xenografts were studied. 125I bound to PHEG-ADR was cleared relatively 
slowly from the circulation and significant turnout uptake was maintained during the period studied. The drug immunoconjugate 
was cleared more rapidly from the circulation with a concomitant decrease intumour uptake as compared with unmodified IgM. 
The biodistribution data indicate that argeting of ADR with IgM 16.88 in this tumour model is not feasible. 
Keywords: Adriamycin; Antibody: Biodegradable polymer; Drug targeting; Poly[N%(2-hydroxyethyl)-L-glutamine] 
1. Introduction 
The targeting of drugs, radioisotopes and toxins with 
the aid of monoclonal antibodies (MoAbs) directed 
against umour-associated antigens is an intensively 
studied strategy in the treatment ofcancer [ 1-3 ]. Most 
studies in which repetitive administration f immuno- 
conjugates ofthese MoAbs was applied were hampered 
by the development of a human anti-mouse antibody 
(HAMA) response [1]. Therefore, human MoAbs 
have become the antibodies of choice in our diagnostic 
and therapeutic studies [4-7 ]. These antibodies can be 
produced on a large scale and have been administered 
to humans in amounts up to 1 g without evoking an 
immune response or other undesirable side effects 
[6,7]. A human IgM designated 16.88 reacting with 
an intracellular cytokeratin-related umour antigen [8 ] 
and homing to permeable cells in the tumour as shown 
by radio-imaging studies was used as targeting vehicle 
in our studies on the development of therapeutically 
active drug immunoconjugates. 
As pointed out earlier [ 1 ], large amounts of chemo- 
immunoconjugates with a molar drug/antibody ratio 
of at least 50 are needed for an effective tumour egres- 
sion if adriamycin (ADR) is employed as the cytostatic 
drug and the use of intermediate drug carriers [9] is a 
prerequisite in order to achieve the appropriate drug 
load of the immunoconjugate in case IgM antibodies 
are used as the targeting vehicle. We found previously 
that immunoconjugates of IgM 16.88 and poly [NS-(2- 
hydroxyethyl)-L-glutamine] (PHEG) show a biodis- 
tribution profile comparable with that of IgM 16.88 per 
se [ 10]. We now have extended these studies to ADR- 
containing immunoconjugates d rived from IgM 16.88 
and PHEG as the drug carrier. The preparation ofcon- 
jugates of ADR and PHEG using a novel acid-labile 
linker based on a maleamic acid derivative and of 
immunoconjugates is described. By the use of these 
linkers the rate of drug release from conjugates in an 
acidic environment is faster by at least one order of 
magnitude as compared to that at neutral pH [ 11,12]. 
The uncharged PHEG was chosen as the drug carrier 
to facilitate the purification of immunoconjugates by 
standard chromatographic techniques. The tumour 
uptake and biodistribution of I25I-labelled PHEG-ADR 
conjugate and of immunoconjugates consisting of ~3 q_ 
labelled antibody and PHEG-ADR were investigated 
in nude mice carrying MRI-H-207 human ovarian turn- 
our xenografts and were compared with the data of IgM 
16.88. The results, in particular the in vivo effect of 
ADR present in immunoconjugates, arediscussed in 
relation to the targeting of the free drug. 
2. Materials and methods 
2.1. Mater ia ls  
The following compounds were obtained from the 
manufacturer indicated and were used as supplied. 2- 
Aminoethanol, Merck, Germany; N,N-carbonyldiimi- 
dazole (CDI), Merck, Germany; dithiothreitol (DTT), 
Merck, Germany; 5,5'-dithio-bis ( 2-nitrobenzoic a id) 
(DTNB), Sigma, USA; 4,4'-dithiodipyridine (DTP), 
Sigma, USA; N-ethoxycarbonyl-2-ethoxy-l,2-dihy- 
droquinoline (EEDQ), Serva, Germany; N-(y-mal- 
eimidobutyryloxy)succinimide, (GMBS), Sigma, 
USA and Fluka, Germany; N-succinimidyl acetate 
(AcOSu), Sigma, USA; N-succinimidyl 4-[N-mal- 
eimidomethyl ] cyclohexane- 1-carboxylate (SMCC), 
Pierce, USA; N-sulfosuccinimidyl 4-[N-maleimido- 
methyl] cyclohexane- 1-carboxylate (sulfo-SMCC), 
Pierce, USA. 
The human IgM MoAb 16.88 was provided by Orga- 
non Teknika/Biotechnology Research Institute, Rock- 
ville MD, USA. 
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The following compounds were prepared as 
described, y-Benzyl-L-glutamate (BLG 11) [13]; y- 
benzyl-L-glutamate N-carboxyanhydride (BLG NCA 
12) [ 10]; poly(y-benzyl-L-glutamate) containing 
cystamide groups (S2-PBLG 13a,b), a mixture of 
bis [ poly (y-benzyl-L-glutamate) ] cystamide (bis- 
PBLG-cystamide 13a) and poly(y-benzyl- L-glu- 
tamate) (PBLG 13b) [ 10]; poly(a- L-glutamic acid) 
containing cystamide groups (S2-PGA 14a,b), a mix- 
ture of bis [ poly (a-L-glutamic acid) ] cystamide (bis- 
PGA-cystamide 14a) and poly(c~-L-glutamic a id) 
(PGA 14b) [10]; high-molecular weight PGA 14b 
[ 14]; cystamine free base from the dihydrochloride 
[15]. 
Buffers were prepared from analytical grade salts, 
filtered and deaerated with nitrogen. Buffer I, 50 mM 
Na2HPO4/H3PO4, 1 mM EDTA, pH 7.5; buffer II, 0.10 
M NaC1, 10 mM Na2HPO4/H3PO4, pH 7.0; buffer III, 
0.10 M NaC1, 50 mM NaH2POJNa2HPO4, 1 mM 
EDTA, pH 6.0; buffer IV, 0.14 M NaCI, 25 mM 
Tris.HC1, pH 8.0; buffer V, 70 mM NaCI, 25 mM 
Tris-HCI, pH 8.0. 
2.2. Methods 
Analytical procedures 
NMR spectra were recorded on Bruker instruments 
operating at 200 or 250 MHz (~H) or 50 MHz (~3C). 
Chemical shifts (3) are given in ppm relative to tetra- 
methyisilane (TMS) or 4,4-dimethyl 4-silapentane 
sodium sulphonate (DSS). In order to replace 
exchangeable protons of water-soluble polymers by 
deuterons, a solution of the polymers in D20 (99.8% 
D) was left to stand at room temperature for 2-3 h and 
was then lyophilized. This procedure was repeated 
once, and spectra were recorded of solutions of the 
polymers in D20 (99.96% D). Thin-layer chromatog- 
raphy (TLC) was performed on silica coated onto plas- 
tic sheets GF254 ( Merck, Germany) using the following 
solvent systems: A, toluene/ethanol (8/2; v/v);  B, 
ethyl acetate/hexane ( 1 / 1 ; v/v)  ; C, n-butanol/acetic 
acid/water (4/1 / 1 ; v/v) [ 10,14]. Polyacrylamide g l 
electrophoresis (PAGE) in the presence of sodium 
dodecylsulphonate (SDS) was performed as described 
[10]. 
Samples for amino acid analysis were hydrolyzed in 
5.8 N HC1 at 110°C for 48 h. Hydrolyses and amino 
acid analyses were performed induplicate. The content 
of polymer- or immunoconjugate-bound ADR was 
determined by quantification of fl-Ala and Asp using 
amino acid analysis. The content of maleimido groups 
was determined by quantification of y-aminobutyric 
acid using amino acid analysis. IgM concentrations 
were calculated from the absorbance at280 nm using 
an absorbance value of 1.4 for a 1 mg/ml solution [10 ]. 
For ADR-containing immunoconjugates he IgM con- 
centration was calculated from the absorbance at 280 
nm after subtracting the contribution of ADR which 
was estimated from the absorbance at490 nm and the 
known ratio of absorbancies at 280 and 490 nm of 
PHEG-ADR. 
The concentration of thiol/disulfide groups bound 
to polymeric arrier or ADR conjugate was determined 
using DTNB [ 16] or DTP [ 17]. 
The concentration of polymer- or protein-bound 
maleimido groups was determined as follows. Solu- 
tions of maleimido-containing conjugate in buffer I 
(0.025q3.100 ml series, ca. 0.5-1 mM maleimido 
groups), Cys (0.050 ml, 2 mM in water) and buffer I
(to give 1.10 ml total assay volume) were mixed and 
the mixture was reacted for 10 min at room temperature. 
A mixture without conjugate was used as the standard. 
Then a solution of DTP (0.100 ml; 2 mM) was added 
to each mixture and after 15 min the increase in absorb- 
ance at 328 nm was determined. The concentration of
maleimido groups was calculated from the depletion in 
the concentration of Cys relative to the standard as 
measured by the Cys-mediated change in absorbance 
at 328 nm due to release of 4'-pyridinthione (molar 
absorbance coefficient 20 800 M-  i cm-  1 ). 
Ultrafiltration and diafiltration 
Ultrafiltration and diafiltration of polymers or pro- 
teins were performed with Amicon stirred cells (400, 
50 and 10 ml) using Amicon YM-10 membranes. Pol- 
ymers were desalted by diafiltration with water until 
the conductivity of the ultrafiltrate was 10-15 p,S, 
which required the addition of 6-8 times the volume of 
water elative to sample volume. 
Characterization fpolymers 
The weight-average and number-average molecular 
weights (Mw and Mn, respectively) of S2-PBLG and 
PHEG copolymers were determined by high-perform- 
ance size-exclusion (HP-SEC)/low-angle laser light 
scattering (LALLS) analysis. S2-PBLG was analyzed 
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Table 1 
Preparation of polymeric arriers and conjugates with 2,2'-oxybis(ethylamine) after polymerization f BLG NCA 12 in dioxane (4 wt%) by 
cystamine (monomer/initiator ratio 48 mol/mol) 
Polymer Yield (%) Mw ( × 10 4) DPw M. ( × 10 4) DPn Mw/Mn dn/dc (ml/g) 
13a,b S2-PBLG-I 93 ~ 3.15 h 144 h 2.18 h 100 h 1.44 0.1127 
13a,b S,-PBLG-II 83 ~ 4.55 h 208 u 3.18 h 145 h 1.43 0.1169 
13a,b S~-PBLG-III 88" 4.90 h 223 h 3.59 h 164 h 1.36 0.1070 
14a,b S2-PGA-IP 71 d 1.94 j 151Y -- -- -- 
14a,b S2-PGA-III-I a 60 ~ 2.11 j 164 j . . . .  
14a,b S2-PGA-III-2 ~ 62 d 2.4cp 193 j . . . .  
15a,b S2-PGA-OEA-BOC u 82 ~ - . . . .  
16a,b S2-PHEG-OEA-BOC b 9Y 6.76 k .... 368 k .... 5.1 lk .... 278 k .... 1.32 0.1565 
17a,b Sz-PHEG-OEA-NH2 crude b 78 ~ 6.66 k .... 378 k'm 5.70 k.... 324 k .... 1.17 0.1556 
17a,b S:-PHEG-OEA-NH2 HMW b - 7.46 k .... 423 k .... 6.54 k''n 371 k .... 1.14 0.1651 
17a,b S2-PHEG-OEA-NH2 LMW b 42 g 4.22 k'm 239 k .... 3 .98  k .... 226  k .... 1.06 0.1557 
aAmount of residual benzyl groups 0.5 mol%. 
hPrepared from 14a,b batch II. 
~Relative to 12. 
dRelative to 13a,b. 
eRelative to 14a,b. 
JRelative to previous conjugate. 
gAverage value relative to crude conjugate. 
hBy HP-SEC/LALLS in DMF. 
JBy viscometry. 
kApparent value, see section 3. 
ruBy HP-SEC/LALLS in 0.1 M sodium acetate, pH 6.0. 
as descr ibed [ 10]. PHEG copolymers  were analyzed 
using three TSK co lumns (G  5000 PW, G 4000 PW, 
G 3000 PW)  (7.8 × 300 mm) in series equi l ibrated in 
0.1 M sodium acetate, pH 6.0, at a flow rate of  1.0 ml /  
min. Refract ive index increments  (dn/dc) at 633 nm 
of  the polymers in the corresponding solvents are g iven 
in Table 1. The weight-average molecular  weight  
(Mw) of S2-PGA was determined by v iscometry [ 10]. 
Western blot of SDS-polyacrylamide g ls 
Proteins were transferred f rom the gel onto 
po ly (v iny l idene  f luoride) (PVDF)  membranes  by 
electrophoresis  in a Transblot  cell (Biorad,  USA)  
using 25 mM Tris-HC1, 0.192 M glycine, 200 ml/1 
methanol ,  300 mg/1 SDS as transfer buffer  [ 18]. Blot- 
t ing was carr ied out for 2 h at 10 V /cm and 0.25 A at 
ambient  emperature,  the membrane being placed at the 
anodal  side of the gel. The blot was then  treated with 
Blotto (50 g/1 Sk im milk, dehydrated,  in phosphate-  
buf fered sal ine ( PB S ) /Tween)  for 2 h at 37°C, washed 
with PBS/Tween and incubated with peroxidase- 
l inked goat ant i -human IgM in PBS ( 1 mg/ml  di luted 
1:16 000)  for 1 h at 37°C. After  3-fold wash ing with 
PBS/Tween the IgM bands were visual ized by a solu- 
t ion contain ing cobalt  chlor ide (0.6 g / l ) ,  
3 ,3 ' -d iaminobenz id ine  (DAB)  (0.3 g / l )  and hydro- 
gen peroxide (0.03 g / l )  in PBS. The react ion was 
stopped by soaking in water. 
Synthetic procedures 
2-( 2-N-te rt-Butoxycarbonylaminoethoxy )ethanol 2
2- (2 -Aminoethoxy)ethano l  1 (7.5 g, 71.3 mmol )  
was dissolved in d ich loromethane (CHzC12) (50 ml)  
in a 250 ml round-bot tomed flask equipped with a mag- 
netic stirrer and a pressure-equal iz ing addit ion funnel. 
A solut ion of  di-tert-butyldicarbonate ((BOC)20) 
(16.8 g, 77.0 mmol )  in d ich loromethane (CH2Clz) 
(50 ml)  was added dropwise over  30 min. After  stirring 
for 3 h at room temperature the solution was di luted 
with diethyl ether (E t20)  ( 100 ml)  and washed with 
sodium phosphate buffer  (0.5 M, pH 5.4, 2 x 50 ml ) ,  
5% NaHCO3 (2 × 50 ml)  and saturated NaC1 solution 
(50 ml) .  The solution was dried (Na2SO4),  fi ltered 
and evaporated to dryness to give 2 as an oil. Y ield 
14.7 g (100%) .  TLC Rf (A )  0.56; IH -NMR (CDC13/ 
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TMS): 6=1.46 (s, 9H, BOC); 3.34 (m, 2H, 
BOCNHCH2-); 3.55 (t, 2H, -OCH2-); 3.56 (t, 2H, - 
CH20-); 3.74 (m, 2H, -CHzOH). 
1-Azido-2-(2-N-tert-butoxycarbonylaminoethoxy)- 
ethane 3
To a stirred and precooled (0°C) solution of 2 ( 14.7 
g, 71.3 mmol) and triethylamine (TEA) (10 ml, 71.6 
mmol) in toluene (200 ml) was added methanesul- 
fonyl chloride (5.52 ml, 71.3 mmol) in an atmosphere 
of nitrogen. After 5 min tetrabutylammonium bromide 
(2.3 g, 7.13 mmol) and a solution of sodium azide 
(NAN3) (38.8 g, 0.60 mol) in water (150 ml) were 
added and the mixture was heated at 60°C for 3 h. The 
mixture was allowed to cool to room temperature, 
diluted with Et20 ( 100 ml) and washed with sodium 
phosphate buffer (0.5 M, pH 5.4, 50 ml) and saturated 
NaC1 solution (50 ml). The solution was dried 
(NazSO 4), filtered and evaporated todryness to give 3 
as an oil. Yield 14.15 g (85.9%). TLC Rf (B) 0.71; 
JH-NMR (CDC13/TMS): 6-- 1.45 (s, 9H, BOC); 3.35 
(m, 2H, BOCNHCH2-); 3.40 (t, 2H, -CH2N3); 3.55 
(t, 2H, -CH20-); 3.65 (m, 2H, -OCH2- ). 
N-tert-Butoxycarbonyl-2,2'-oxybis(ethylamine) 
hydrochloride (BOC-OEA 4) 
A solution of compound 3 ( 14.15 g, 61.4 mmol) in 
a mixture of methanol (MeOH) (200 ml) and chlo- 
roform (CHC13) (14 ml) was hydrogenated in the 
presence of 10% Pd/C (1.4 g) for 1 h. The catalyst 
was removed by filtration using hyflo, the hyflo was 
washed with additional MeOH (50 ml) and the com- 
bined filtrates were evaporated to dryness. The solid 
residue was triturated with Et20 ( 100 ml) and the pre- 
cipitate 4 was isolated by filtration in a yield of 10.25 
g (69.3%). TLC Rf (C) 0.58; m.p. 104-110°C; ~H- 
NMR (D20/DSS); 6= 1.44 (s, 9H, BOC); 3.20 (dt, 
2H, -CH2NH2); 3.30 (t, 2H, BOCNHCH2-); 3.61 (t, 
2H,-OCH2-); 3.76 (t, 2H,-CH20-).  13C-NMR 
(D20/DSS): 6=30.405 (q,-(CH3)3); 41.892 (t, 
-CH2NH2); 42.462 (t, BOCNHCH2-); 68.971 (t, 
-CH20-) ; 72.426 (t, -OCH2-) ; 83.906 (s, 
-C(CH3)3); 6 161.094 (S, -OCONH-). IR (KBr): 
3365, 1688, 1530, 1175, 1110 cm -1. Fast atom bom- 
bardment mass spectrometry (FABMS) (glycerol): 
m/z 205.2 [M + H] +; C9H2oN203 requires 204.73. 
4-( N-tert-Butoxycarbonylamino )- l-butanol 6 
4-Amino-l-butanol 5 (7.5 g, 84.1 mmol) was dis- 
solved in CH2C12 (50 ml) in a 250 ml round-bottomed 
flask equipped with a magnetic stirrer and a 
pressure-equalizing addition funnel. A solution of 
(BOC)20 (19.8 g, 90.7 mmol) in CHzC12 (50 ml) 
was added dropwise over 30 min. After stirring for 3 h 
at room temperature the solution was diluted with Et20 
(100 ml) and washed with sodium phosphate buffer 
(0.5 M, pH 5.4, 2 × 50 ml), 5% NaHCO3 (2 × 50 ml) 
and saturated NaC1 solution (50 ml). The solution was 
dried (NazSO4) , filtered and evaporated todryness to 
give 6 as an oil. Yield 15.9 g (100%). TLC Re (A) 
0.59; ~H-NMR (CDC13/TMS): 6=1.44 (s, 9H, 
BOC); 1.59 (m, 4H,-CH2CH2-); 3.15 (q, 2H, 
BOCNHCH2-); 3.67 (q, 2H, -CHzOH ). 
1-Azido-4-(N-tert-butoxycarbonylamino)butane 7 
To a stirred and precooled (0°C) solution of 6 ( 15.9 
g, 84.1 mmol) and TEA ( 12 ml, 84.1 mmol) in toluene 
(200 ml) was added methanesulfonyl chloride (9.64 
ml, 84.1 mmol) in an atmosphere of nitrogen. After 5 
min tetrabutylammonium bromide (2.71 g, 8.41 
mmol) and a solution of NaN3 (45.7 g, 0.70 mol) in 
water ( 150 ml) were added and the mixture was heated 
at 60°C for 3 h. The mixture was allowed to cool to 
room temperature, diluted with Et20 (100 ml) and 
washed with sodium phosphate buffer (0.5 M, pH 5.4, 
50 ml) and saturated NaC1 solution (50 ml). The solu- 
tion was dried (Na2SO4), filtered and evaporated to
dryness to give 7 as an oil. Yield 18.12 g (100%). TLC 
Re (B) 0.59; IH-NMR (CDC13/TMS): 8= 1.45 (s, 
9H, BOC); 1.60 (m, 4H, -CHzCH2-); 3.15 (q, 2H, 
BOCNHCH2-); 3.30 (t, 2H, -CHzN3). 
N-tert-Butoxycarbonyl- l, 4 diaminobutane hydrochlo- 
ride (BOC-AB 8) 
A solution of compound 7 ( 18.12 g, 84.1 mmol) in 
a mixture of MeOH (200 ml) and CHC13 ( 18 ml) was 
hydrogenated in the presence of 10% Pd/C ( 1.8 g) for 
1 h. The catalyst was removed by filtration using hyflo, 
the hyflo was washed with additional MeOH (50 ml) 
and the combined filtrates were evaporated todryness. 
The solid residue was triturated with Et20 (100 ml) 
and the precipitate 8 was isolated by filtration in a yield 
of 12.45 g (65.5%). TLC: Re (C) 0.64; m.p. 149- 
153°C (147-148°C [19]); ~H-NMR (D20/DSS): 
6= 1.44 (s, 9H, BOC); 1.50-1.75 (m, 4H, 
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-CHzCH2-); 3.03 (t, 2H, -CH2NH2) ; 3.12 (t, 2H, 
BOCNHCH2-).I3C-NMR (DzO/DSS) : 6 = 26.805 (t, 
NHCHzCH2-); 28.774 (t,-CH2CHzNH2); 30.412 
(q, - (CH3) 3) ; 41.904 (t, -CH2NH 2 and t, 
BOCNHCH2-) ; 83.715(s, -C(CH3)3); 161.070 
(s, -OCONH-). IR (KBr): 3362, 1689, 1530, 1175 
cm -~. FABMS (glycerol): m/z 189.2 [M+H]+;  
C9H2oN202 requires 188.27. 
ADR derivatives 9 and 10 
The ADR derivatives S-acetylthioacetyl-/3-Ala-Asp- 
ADR (SATA-/3-Ala-Asp-ADR 9) and S-acetylthioac- 
etyl-/3-Ala-/3-methyl,dehydroAsp-ADR (SATA- 
/3-Ala-/3-methyl,dehydroAsp-ADR 10) [ 11,12] will 
be described in detail elsewhere [20]. 
Conjugate of S2-PGA 14a, b and N-tert-butoxycar- 
bonyl-2,2'-oxybis(ethylamine) 4 (S2-PGA-OEA-BOC 
15a, b ) 
To a stirred solution of 14a,b batch II, H-form (5.50 
g, 42.6 mmol) in DMF (120 ml) 4 (1.026g, 4.26 
mmol), TEA (0.594 ml, 4.26 mmol) and a solution of 
EEDQ (1.264 g, 5.11 mmol) in DMF (10 ml) were 
successively added and the mixture was stirred for 3 
days at room temperature. The mixture was dissolved 
in 0.2 M sodium phosphate buffer, pH 7.5 (700 ml) 
and filtered (0.2 /~m). The solution was dialyzed 
against 0.2 M NaC1 ( 1 × 20 1) and water (4 × 20 1) at 
4°C and was finally lyophilized. Yield 6.52 g (39.3 
mmol, 92%) of 15a,b, sodium salt. 1H-NMR (D20): 
6= 1.40 (s, 8.89 mol% of 9H relative to Glu, - 
(CH3)3); 2.00, (m, 2H, Glu /3-CH2); 2.33 (m, 2H, 
Glu "y-CH2) ; 3.24 (t), 3.38 (broad s) and 3.58 (m) 
(8.91 mol% of 8H relative to Glu, -CHzCH 2- 
OCH2CH2-); 4.33 (s, 1H, Glu ce-CH2). 
A solution of the polymer in water (300 ml) was 
slowly poured into 0.1 N HCI (500 ml) under vigorous 
stirring. The precipitate was isolated by centrifugation 
(3000 rpm, 8 min) and was resuspended in 0.01 N HC1 
(5 × 400 ml) each time followed by centrifugation. 
The suspension of the polymer in water was finally 
lyophilized yielding 5.09 g (34.9 mmol, 82%) of 
15a,b, H-form. For ~H-NMR a sample was dissolved 
in 0.25 M sodium phosphate, pH 7.5, dialyzed against 
water, filtered (0.45/~m), and pretreated with D20 as 
described above. 
Conjugate of Se-PHEG and N-tert-butoxycarbonyl- 
2, 2'-oxybis(ethylamine) 4 (S2 -PHEG- OEA-BO C 
16a, b ) 
To a stirred solution of 15a,b, H-form (4.80 g, 32.9 
mmol) in DMF (75 ml) saceharinic acid (7.14 g, 39.0 
mmol) and N,N'-carbonyldiimidazole (CDI) (7.11 g, 
43.9 mmol) were successively added. After 30 min at 
room temperature 2-aminoethanol (29 ml, 0.484 mol) 
was added and the mixture was stirred for 4 days at 
room temperature. The mixture was dissolved in 0.25 
M sodium phosphate buffer, pH 7.5 ( 600 ml), acidified 
to pH 6.0 with 4 M H3PO 4 and filtered (0.45/~m). The 
solution was dialyzed against 0.2 M NaC1 (3 × 20 1) 
and water (4 × 201) at 4°C and was finally lyophilized. 
Yield 5.67 g (30.6 mmol, 93%) of 16a,b. ~H-NMR: 6 
= 1.40 ( s, 9.1 mol% of 9H relative to Glu, - (CH3) 3) ; 
2.07 (m, 2H, Glu/3-CH2) ; 2.38 (m, 2H, Glu T-CH2) ; 
3.29 (t) and3.60 (t) (95.8 tool% of 4H relative to Glu, 
-NDCHzCH2OD; 9.1 mol% of 8H, -CH2CH 2- 
OCHzCH2-); 4.25 (s, 1H, Glu c~-CH2). 
Conjugate of S2-PHEG and 2,2'-oxybis(ethylamine) 
(S2-PHEG-OEA-NH2 17a, b) 
Conjugate 16a,b (2.50 g, 13.5 mmol) was dissolved 
in TFA (70 ml) with stirring at room temperature. 
After 8 min the solution was evaporated to dryness in 
vacuo within the next 5 min and the oily residue was 
dissolved in 0.25 M sodium phosphate buffer, pH 8.0 
( 150 ml). The pH of the solution was adjusted to 6.0 
with 4 M NaOH. The solution was filtered (0.45/~m), 
concentrated to 100 ml by ultrafiltration, desalted by 
diafiltration against water (700 ml) and finally lyo- 
philized. Yield 1.94 g (10.5 mmol, 78%) of 17a,b, 
phosphate salt. ~H-NMR (D20): 6= 2.07 (m, 2H, Glu 
/3-CH2); 2.38 (m, 2H, Glu y-CH2); 3.28 (t) and 3.60 
(t) (89.3 tool% of 4H relative to Glu, 
-NDCH2CHzOD); 3.18 (t) and 3.71 (t) (9.0 mol% 
of 4H, spacer-CH2); 4.26 (s, IH, Glu ol-CH2). Other 
spacer-CH2 signals are buried under the deuterium oxy- 
ethylamide signals. 
Conjugate of PHEG and 1,4-diaminobutane (PHEG- 
butyl-NH2 18) 
The conjugate of PHEG and 1,4-diaminobutane 
(PHEG-butyl-NH2 18) was prepared from high- 
molecular weight PGA 14b (Mw 73 000) and 8 
according to the procedure described above. ~H-NMR 
(D20) : 6= 2.09 m (2H, Glu/3-CH2) ; 2.38 m (2H, Glu 
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y-CH2) ; 3.30 (t) and 3.61 (t) (90 mol% of 4H relative 
to Glu, -NDCHRCH2OD) ; 1.59 (m), 2.98 (t) and 3.20 
(m) ( 10 mol% of4H, CH2CH2CH2CH2); 4.25 s ( 1H, 
Glu ce-CH2). 
Fractionation of PHEG carriers by SEC 
Conjugate 17a,b was fractionated in batches of 110 
mg by gel filtration on a TSK Fraktogel HW-55S col- 
umn (95 × 2.6 cm; 500 ml) equilibrated in buffer II as 
described previously [10] yielding a 'high molecular 
weight' (HMW) and a 'low molecular weight' 
(LMW) polymer fraction which were desalted by 
diafiltration against water and then lyophilized. The ~H- 
NMR spectrum of the LMW fraction was identical with 
that of the parent polymer. 
volume were pooled and the solution of 19a,b (300 
ml) was concentrated to 20.7 ml by ultrafiltration. The 
solution was analyzed for the content of thiol groups 
after reduction using the Cys/DTP assay and for the 
content of Glu (cartier), T-aminobutyric acid (mal- 
eimide linker) and/3-Ala (ADR) by amino acid anal- 
ysis after acidic hydrolysis. 
To allow radiolabelling of the ADR conjugate, 
amino groups were introduced by a slight modification 
of the above procedure. The solution of PHEG-bound 
maleimide in buffer I was reacted with cysteamine ( 10 
mol% of maleimido groups) in buffer I for 10 min at 
room temperature. Subsequently, the coupling of the 
ADR derivative was performed as described. 
Conjugate of Se-PHEG-OEA-NH2 17a, b and thioace- 
tyl-~-Ala-Asp-ADR (S2-PHEG-ADR 19a, b) 
To a solution of 17a,b LMW ( 120.0 mg, 0.65 mmol 
of carrier; 0.058 mmol of NH2) in DMSO (5.25 ml) a 
solution of TEA (0.13 mmol) in DMSO (0.266 ml) 
and GMBS (55.9 mg, 0.20 mmol) were successively 
added. After stirring the solution for 60 min. at room 
temperature, maining amino groups were acylated by 
the addition of N-succinimidyl acetate (AcOSu) ( 31.3 
mg, 0.20 mmol) and the solution was stirred for an 
additional 90 min at room temperature. The solution 
was mixed with buffer I (27.0 ml) and the solution 
was filtered (0.45 /xm). The filtrate was applied to a 
Sephadex G-25 column. The polymer-containing frac- 
tions were pooled (48 ml) and the PHEG-bound mal- 
eimide concentration ( 1.039 mM) was determined by 
the Cys/DTP assay. The PHEG-maleimide conjugate 
(47.5 ml) was concentrated to 18.0 ml by ultrafiltration 
and buffer (2.0 ml) was added. To the solution of 
PHEG-bound maleimide in buffer I (12.4 ml) DMF 
(6.2 ml), 9 (47.8 mg, 0.056 mmol) and a solution of 
NH2OH (0.19 mmol) in buffer I (0.38 ml) were sub- 
sequently added with stirring. The reaction mixture was 
stirred for 45 min at room temperature protected from 
light. The solution was applied to a column of Sephadex 
LH-20 (56 × 2.6 cm) equilibrated in DMF/buffer I 
(1/2 v/v; pH 7.5). Elution took place with the same 
solvent at a flow rate of 120 ml/h. The fractions eluting 
at the void volume were pooled and the solution was 
applied to a column of Sephadex G-25 equilibrated in
buffer I. Elution took place with the same solvent at a 
flow rate of 270 ml/h. The fractions eluting at the void 
Conjugate of PHEG and thioacetyl-C3-Ala-t~- 
methyl, dehydroAsp-ADR (PHEG-ADR 20) 
To a solution of 18 (29.6 mg, 0.16 mmol of carrier; 
0.016 mmol of NH2) in 50 mM Na2HPO4/H3PO4, 1
mM EDTA buffer, pH 8.5 ( 1.5 ml) sulfo-SMCC (21.3 
mg, 0.048 mmol) was added and the mixture was 
stirred for 30 min. at room temperature. The reaction 
mixture was mixed with buffer I (28.5 ml) and the 
solution was filtered (0.45 /zm). The filtrate was 
applied to G-25 (PD-10) columns (14 columns; 2.0 
ml sample volume each). The polymer-containing 
fractions were pooled (45 ml) and the PHEG-bound 
maleimide concentration (0.121 mM) was determined 
by Cys/DTNB assay. To the solution of PHEG-bound 
maleimide in buffer I (42 ml) 10 (9.0 mg, 9.1 /xmol) 
and a solution of NH2OH (0.45 mmol) in buffer I (0.9 
ml) were subsequently added with stirring. The reac- 
tion mixture was stirred for 45 min. at room temperature 
protected from light. Part of the solution (21 ml) was 
frozen and kept overnight in the freezer. A mixture of 
the solution (21 ml) and DMF ( 10 ml) was applied to 
a column of Sephadex LH-20 (31 × 2.6 cm) equili- 
brated in DMF/buffer I (1/2 v/v; pH 7.5). Elution 
took place with the same solvent at a flow rate of 70 
ml/h and the fractions eluting at the void volume were 
pooled. The other part of the reaction mixture was 
treated similarly. Both polymer solutions obtained after 
LH-20 purification were pooled and the solution was 
applied to a column of Sephadex G-25 equilibrated in
buffer I. Elution took place with the same solvent at a 
flow rate of 270 ml/h. The fractions eluting at the void 
volume were pooled and the solution of 20 ( 150 ml) 
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was concentrated to25 ml by ultrafiltration. The solu- 
tion was stored at 4°C. 
Immunoconjugate of IgM 16.88 and Sz-PHEG-ADR 
19a, b (IgM-PHEG-ADR 22) 
To a solution of IgM 16.88 ( 13.75 mg) in buffer I
(2.5 ml) was added a solution of GMBS (0.6/zmol; 
40 mol of GMBS/mol of IgM) in DMF (0.060 ml). 
The reaction mixture was kept at room temperature for 
1 h and excess reagent and low-molecular weight reac- 
tion products were removed by gel filtration on 
Sephadex G-25 (PD-10) columns equilibrated in buf- 
fer III. The eluate containing maleimido-activated IgM
16.88 (GMB-IgM 21) was stored at 4°C and used 
within 1 h. The concentration flgM-bound maleimido 
groups as determined by the Cys/DTNB depletion 
assay was 7.37 x 10 -5 M (degree of substitution 18 
mol of maleimido groups/mol of IgM). To a solution 
of 19a,b (batch 3, 7.9 rag) in buffer I (2.2 ml) were 
added buffer I (2.2 ml) and a solution of Cys (25 
/zmol) in buffer I (0.1 ml). The mixture was incubated 
for 20 min at 37°C. Subsequently, a solution of DTT 
(0.25 mmol) in buffer I (0.5 ml) was added and the 
mixture was incubated for 1 h at 37°C. Excess reagent 
and low-molecular weight reaction products were 
removed by repeated gel filtration on Sephadex G-25 
(PD-10) columns equilibrated in buffer III. The eluate 
containing reduced 19a,b was stored at 4°C and used 
within 1 h. The concentration of free polymer-bound 
thiol groups as determined by the DTNB assay was 
3.8 X 10 -5 M. Solutions of 21 (2.0 ml; 0.147/zmol of 
maleimido groups) and reduced 19a,b ( 3.8 ml; 0.144 
/xmol of thiol groups) were mixed with stirring and the 
reaction was allowed to proceed for 15 h at 4°C. A 
solution of cysteamine (0.22 /xmol; 1.5 mol of cys- 
teamine / mol of maleimido groups) in buffer III (0.022 
ml) was added and the mixture was incubated for 30 
min at room temperature. Subsequently, the reaction 
mixture was applied on a column of TSK Fraktogel 
HW-55S (80 x 2.6 cm; 425 ml) equilibrated in buffer 
IV. Elution was performed with buffer IV as the eluent 
at a flow rate of 35-40 ml/h and fractions of 5.4 ml 
were collected. The UV absorbance of the eluate was 
monitored at 280 and 490 nm. Fractions 23 and 24 
containing the immunoconjugate IgM-PHEG-ADR 22 
were pooled and the solution was diluted with an equal 
volume of 25 mM Tris. HC1 buffer, pH 8.0. The solu- 
tion was applied on a column of Q-Sepharose Fast Flow 
( 12 x 1.6 cm; 24 ml) equilibrated inbuffer V. Ste t
elution was performed with 25 mM Tris. HC1 bu 
pH 8.0, containing sequentially 70, 100, 150, 200, 
300 and 400 mM NaC1 at a flow rate of 25-30 t 
The UV absorbance of the eluate was monitored a 
and 490 nm. Unreacted 19a,b was eluted with bt 
containing 70-150 mM NaC1 and 22 was desorb~ 
buffers containing 200-250 mM NaC1. The unre~ 
IgM was mainly eluted by buffers containing 250 
mM NaCI. Immunoconjugate fractions were coi 
trated by ultrafiltration and sterilized by filtr 
through a 0.20 /zm filter. HP-SEC analysis was 
formed on a Zorbax GF-450 (300×7.8 mm) co 
using 0.20 M sodium phosphate buffer, pH 7.0 a 
eluent at a flow rate of 1.0 ml/min. The absorban 
the column eluate was simultaneously monitored a 
and 500 nm. 
Radiolabelling of lgM 16.88 and S2-PHEG-ADR J 
Radio-iodination of IgM 16.88 with t3JI was ca 
out prior to preparation of immunoconjugate folio 
the iodogen labelling procedure [ 10]. Protein (30 
was incubated with Na 1311 (50 /xCi/mg proteil 
vials coated with 100/zg iodogen in PBS, pH 6.~ 
5 min at 0°C. Labelling of IgM 16.88 with 3H 
accomplished by reaction of the protein with N-s~ 
nimidyl [ 2,3-3H ]propionate (50/zCi/mg proteil 
DMF/PBS 1/4 v/v, pH 8.0, for 2 h at i 
temperature. Conjugate 19a,b containing cystean 
derived amino groups (see above) was labelle, 
reaction with N-succinimidyl-3- (4-hydro~ 
[ 1251] iodophenyl) propionate (Bolton-Hunter 
gent) (50/zCi/mg conjugate) in phosphate buffel 
8.0. Excess non-bound reagents were removed b, 
filtration on prepacked Sephadex G-25 co l t  
(PD10, Pharmacia, Sweden) equilibrated in PBS 
Determination f immunoreactivity by enzyme-li 
immunoassay ( E1A ) 
Method A: active immunoreactivity 
Colon tumour-associated antigen CTA-1 
obtained by Nonidet extraction of HT-29 cells follc 
by ammonium sulfate precipitation at 20% satur~ 
[8]. Microtiter plates were coated ( 110/xl/well) 
a solution of CTA-1 in PBS (5/zg/ml) for 15 at 
The wells were blocked by treatment with Blotto 
/xl/well) for 15 h at 4°C followed by washing 
PBS/Tween. Solutions of IgM or 22 were ser 
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diluted across the plate (100/~l/well) and incubated 
for 1 h at 20°C. After 3-fold washing with PBS/Tween 
the plate was incubated with horseradish peroxi- 
dase(HRP)-linked goat anti-human IgM in PBS (1 
mg / ml diluted 1 : 16 000) for 1 h at 20°C. After washing 
with PBS/Tween (three times) and water the plates 
were incubated with a solution ( 100/zl/well) contain- 
ing 3,3',5,5'-tetramethylbenzidine (TMB) (0.3 mM) 
and urea hydrogen peroxide ( 1.3 mM). The reaction 
was stopped with 4 N HzSO 4 (25 /xl/well) and the 
absorbance at 450 nm was measured using a plate 
reader. The titre is defined as the reciprocal concentra- 
tion of IgM or immunoconjugate giving half of the 
maximum absorbance and is expressed as % relative to 
IgM. 
Method B: passive immunoreactivity 
Microtiter plates were coated (110 /zl/well) with 
serially diluted solutions of IgM or 22 for 1 h at 20°C. 
The wells were blocked by treatment with Blotto (250 
/xl/well) for 15 h at 4°C followed by threefold washing 
with PBS/Tween. The plate was then incubated with 
HRP-linked goat anti-human IgM and end-point deter- 
mination was carried out as described above. 
In vitro release of ADR from PHEG-ADR conjugates 
To study the release of ADR and ADR-related 
extractable products, PHEG-ADR conjugates 20 were 
incubated at a final anthracycline concentration f 10 
mM in 50 mM sodium phosphate buffer, pH 6.0 or 7.5 
at 37°C. After various incubation times a sample (0.20 
ml) was mixed with 0.4 M borate, 0.4 M KC1 buffer, 
pH 9.0 ( 1.0 ml) and a solution of daunomycin (internal 
standard) using a vortex mixer for 15 sec. CHC13/ 
CH3OH (4/1 v/v; 2.0 ml) was added and the suspen- 
sion was mixed using a vortex mixer for 30 s. After 
centrifugation the aqueous layer was discarded and the 
organic layer was evaporated under a stream of nitro- 
gen. The residue was dissolved in CH3OH (0.15 ml) 
and the solution (0.020 ml) was analyzed by HPLC 
using a RP-/xBondapak C~8 column (300 × 3.9 mm; 10 
/xm particle size) (Waters). The eluent was prepared 
by mixing solvent A (CH3OH/0.3 w/v % NH4OAc in 
water 3/2; v/v) and solvent B (CH3OH) in a 85/15 
(v/v) ratio. The flow rate was 1.0 ml/min. The absorb- 
ance of the eluate was monitored at 254 nm. The 
amounts of ADR were determined from the peak areas 
using a calibration curve. 
Cytotoxicity experiments 
HT-29 human colon adenocarcinoma cells were 
grown in M 505 culture medium supplemented with 
10% heat-inactivated fetal calf serum (FCS) at 37°C 
in an atmosphere containing 5% CO2 maintained atpH 
6.0 or 7.5. Cell cultures were passaged twice weekly 
after detachment from the culture flasks using trypsin/ 
EDTA. Inhibition of cell growth was measured as fol- 
lows. Suspensions of the cells in culture medium 
supplemented with FCS (0.100 ml; 2 × 10 4 cells/ml) 
were pipetted into the wells of microtiter plates and 
incubated for 4 h to allow attachment ofthe cells to the 
surface. Stock solutions of ADR or 20 in PBS (up to 1 
mg ADR-equivalents/ml) were serially diluted with 
culture medium supplemented with FCS and the solu- 
tions thus obtained (0.100 ml) were added to the cells. 
The cells were grown in the presence of PHEG-ADR 
or ADR at pH 6.0 and 7.5 for 1, 3 or 5 days at 37°C. 
The cells were then washed and incubated in fresh 
medium at pH 7.5 until day 7. After this period viable 
cells were determined with the 3-(4,5-dimethylthiazol- 
2-yl)-2,5-diphenyl tetrazolium bromide (MTT)/for- 
mazan procedure [ 21 ]. A solution of MTT in culture 
medium (0.050 ml; 1 mg/ml) was added to each well 
and the cells were incubated for 4 h at 37°C. The culture 
medium was removed, DMSO (0.100 ml) was added 
to solubilize the MTT/formazan products generated by 
viable cells and the absorbance at540 nm was meas- 
ured. This value is taken as a relative measure of the 
concentration of viable cells. The inhibition of cell 
growth by 20 is expressed as the ratio of the ID~o value 
and the IDso value of ADR. 
Biodistribution and tumour uptake of 3H-labelled IgM 
16.88, 1251-1abelled S2-PHEG-ADR 19a, b and 1311- 
labelled IgM-PHEG-ADR 22 in athymic nude mice 
The human ovarian tumour line MRI-H-207 is an 
undifferentiated adenocarcinoma originally derived 
from a patient with generalized peritoneal metastases 
and considerable malignant involvement of both ova- 
ries [ 22]. Xenografts of MRI-H-207 were established 
by subcutaneous injection of 5 × 10 6 cells into the left 
and fight flank of athymic nude HSD mice (9 mice/ 
compound). The tumours were grown for 3 weeks, at 
which time the weight was usually between 100 and 
500 mg. 150/xl of a solution containing either equal 
amounts (150/xg; 1 /zCi) of 13q-labelled 22 and 3H- 
labelled IgM or 150/~g ( 1.5/zCi) of 12~I-labelled 19a,b 








HN ~iH2~O H-~-NHCI O ~HCH2CH2 --S~ + H--~NHCHCO ~- H 
H I  II CH~|  J C~H2 | CH~ b , H~ 
o o £ 
d d d 
BLG 
11 
BLG NCA bis-PBLG-cystamide PBLG 
12 13a 13b 
13a,b S2-PBLG 
a: triphosgene, THF 
b: cystamlne, dioxane 
c: methanesulphonic acid, anisole, TFA 
l c 
H-~HCI HGO 1"' pH2 |I 2 NHCH2CH2 ~] + H-- [~--NHCl CO~OH ] CIH2 1 ~H




Fig. 1. Preparation of S2-PGA 14a,b by polymerization of BLG NCA 12 using cystamine as the initiator followed by cleavage of benzyl ester 
groups. 
in PBS was injected i.v into the tail vein of mice fol- 
lowed by injection of 50/_d of PBS in order to minimize 
the loss of labelled compound by bleeding. At 6, 24 
and 48 h after administration, groups of three mice per 
compound were killed. The following tissues were col- 
lected: tumours; liver with gall-bladder; kidneys, with- 
out fat and adrenals; spleen; heart; lungs, muscle 
(tibialis) and thyroid with surrounding cartilage. 
Blood was collected by vena cava (abdominal) punc- 
ture under ether anaesthesia and K-EDTA was added. 
Urine was collected by bladder puncture and faeces 
were collected from the intestine. Blood, urine and 
tissues were weighed, and radioactivity was determined 
with a well-type y-counter (Packard 5530). Data from 
tumours below 100 mg were not used. After storage of 
the samples for 2 months at - 20°C the 3H activity was 
measured by liquid scintillation after combustion ofthe 
samples. The activity is expressed as % of the dose 
administered per g of tissue, blood or urine (% dose/ 
g). 
3. Results 
3.1. Preparation of functionalized PHEG carrier 
PGA containing a terminal disulfide group (S2-PGA 
14a,b) is used as the starting material for the selective 
coupling of polymer-bound ADR with antibodies. 
Polymer 14a,b was prepared by the method of Kato et 
al. [3] as described previously [ 10] in which the thiol 
group is introduced at the C-terminal polymer end 
(Fig. 1; Table 1). BLG 11 was converted to the N- 
carboxyanhydride (BLG NCA 12) which was poly- 
merized in dioxane using cystamine as the initiator. 
The polymer obtained is a mixture of bis-PBLG-cys- 
tamidel3a nd PBLG 13b [3]. The benzyl side chains 
of the polymer mixture were cleaved with methanesul- 
phonic acid/TFA in the presence of anisole to scavenge 
benzyl cations yielding 14a,b. Separation of the poly- 
mer into cystamide-terminated PGA (bis-PGA-cys- 
tamide 14a) and PGA 14b [ 10] was omitted because 
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H2N--CH2--R--CH2--OH 1, 5 
l (BOC)20, CH2Cl2, rT, 3 h 
(CH3)3COCONH ~H2~H2- -OH 2, 6 
1: CH3SO2Cl, TEA, toluene, 0°C, 5 min 
2: aq. NaN 3, Bu4N+Br', 60 Oc, 3 h 
(CH3)3COCON H ~CHz--R -CH2 -~J 3 3, 7 
H2,10 % Pd/C, CH3OH/CHCl3, 1 h 
(CH3)3COCON H -CH2-~ -CH2 --N H2.HCI 4, 8 
1-4: R= --CH2--O-CH 2 -  
5-8: R= ~H2CH 2-  
]Fig. 2. Preparation of monosubstituted iamine spacers BOC-OEA 
4 and BOC-AB 8. 
purification of the PHEG-containing immunoconjugate 
could be accomplished by ion-exchange chromatog- 
raphy as discussed below. 
The introduction of maleimido r amino groups onto 
PHEG to allow the subsequent coupling of drug deriv- 
atives was attempted by activation of the hydroxyl 
groups of the polymer. PHEG was activated by p- 
tosylchloride [ 23,24] tresylchloride [ 24] and p-nitro- 
phenylchloroformate [25,26] and the activated 
polymer was reacted with N-maleimido-1,4-diamino- 
butane or BOC-AB 8. These experiments resulted in 
partial formation of insoluble (crosslinked) polymers, 
low degrees of spacer substitution and the presence of 
polymer-bound activating roups remaining after the 
coupling reaction. The maleimido group of N-maleim- 
ido- 1,4-diaminobutane proved to be unstable when the 
free base was generated from the hydrochloride in 
organic solvents with TEA, probably due to nucleo- 
philic Michael-type addition on the double bond. 
The results prompted us to develop an alternative 
route to prepare PHEG carriers having functional 
amino groups for attachment of ADR derivatives 
described below in addition to polymer-bound disulfide 
groups for the coupling to antibody starting from 14a,b 
(Fig. 2 and 3). In order to prevent crosslinking of pol- 
ymer chains upon introduction of diamine-containing 
spacers, the monosubstituted BOC-derivatives of 2,2'- 
oxybis(ethylamine) 4 and 1,4-diaminobutane 8 were 
prepared using the procedure described by Mattingly 
[19] (Fig. 2). Polymer 14a,b was reacted with 10 
mol% of BOC-OEA 4 using EEDQ as the coupling 
agent in DMF as described previously for the coupling 
of adriamycin to PGA [27] to give S2-PGA-OEA- 
BOC conjugate 15a,b as the sodium salt with a degree 
of substitution of 9.1 mol% of spacer (Fig. 3). The 
conjugate was converted to the acid form by precipi- 
tation in 0.1 M HC1. The BOC group proved to be 
stable under these acid conditions as shown by 1H- 
H-'~NHCI HOOt - - - --[--NHCi HCO 1 I I I  ICH2 I  O I I I  ~ 2 |  iIO / NHCH2CH2 --S 1 + H--'~-NHCI HCO~-- - - - ~[-NHCI HCO / /  CIH2 i ~  |O / / I  ~ 2 I CI  O 









15a,b S2-PGA-OEA-BOC R 1 = OH, R 2 = COOC(CH3) 3 
16a,b S2-PHEG-OEA-BOC R 1 = NHCH2CH2OH , R 2 = COOC(CH3) 3 
17a,b S2-PHEG-OEA-NH 2 R1 = NHCH2CH2OH, R2 = H 
Fig. 3. Structure of conjugates of disulfide-terminated polymeric arriers and 2,2'-oxybis (ethylamine) prepared from S2-PGA 14a,b. 
256 C.J.T. Hoes et al. / Journal of Controlled Release 38 (1996) 245-266 
NMR. The remaining carboxyl groups of the PGA- 
spacer graft were fully converted to 
2-hydroxyethylamide groups as described previously 
for the preparation of PGA-peptide conjugates [27] 
yielding the S2-PHEG-OEA-BOC conjugate 16a,b. 
The conversion of acid groups to 2-hydroxyethylamide 
groups was confirmed by ~H-NMR. Subsequently, the 
BOC group was removed to give the S2-PHEG-OEA- 
NH2 conjugate 17a,b in an overall yield of 59% relative 
to 14a,b. Elution of 17a,b on a high porosity gel filtra- 
tion column (TSK Fraktogel HW-55S) shows a broad 
molecular weight range as discussed previously [10]. 
Prior to further coupling steps the cartier was fraction- 
ated by gel filtration and only the low molecular weight 
fraction designated LMW [ 10] was used in the prep- 
aration of ADR conjugates. 
The degree of substitution of 14a,b with 4 could be 
varied by adjusting the molar ratio of polymer and 
spacer. When using 5 mol% of spacer, 17a,b conjugates 
with 4.1-4.5 tool% degree of substitution were 
obtained. Similarly, use of 20 and 30 mol% spacer 
yielded conjugates with a degree of substitution of 18 
and 26 tool%, respectively. 
The use of 2-pyridyldithio-protected PGA (PDT- 
PGA) instead of 14a,b was initially attempted in the 
above procedure. PDT-PGA was obtained by reduction 
of 14a,b followed by covalent chromatography using 
thiopropyl-Sepharose and protection of thiol-PGA as 
the PDT derivative as described previously [10]. A 
significant loss of PDT groups was observed after the 
coupling step with 2-aminoethanol indicating decom- 
position by the strongly basic amine, although polymer- 
bound thiol groups could still be generated by reduction 
with DTT. These results prompted us to change to the 
use of 14a,b due to the enhanced stability of the disul- 
fide moiety in the presence of 2-aminoethanol. 
A conjugate of PHEG and 1,4-diaminobutane 
designated as PHEG-butyl-NH218 was obtained from 
high-molecular weight (Mw 73 000) PGA without 
thiol end groups 14b [ 14,27] and 8 using the method 
described above. The degree of spacer substitution was 
10 mol% as determined by ~H-NMR. 
3.2. Molecular weights of polymeric arriers 
Analysis of the molecular weight distribution of 
three batches of S2-PBLG 13a,b by HP-SEC/LALLS 
shows a major fraction of medium-sized average 
molecular weight (Mw, Mn) or average degree of 
polymerization (DPw, DPn) (Table 1). The polymer 
batches contain a minor fraction of high-molecular 
weight which may be due to aggregation [28] and the 
HP-SEC/LALLS data of this fraction were not used in 
the calculation of molecular weight averages. Compar- 
ison of the weight-average d grees of polymerization 
(DPw) of different batches of S2-PGA 14a,b as deter- 
mined by viscometry with the values of the parent 
PBLG batches indicates that some chain scission, in 
the order of 0.07-0.19% of amide bonds, had occurred 
as a result of the acid deprotection step. S2-PHEG- 
OEA-BOC 16a,b and various batches of S2-PHEG- 
OEA-NH2 17a,b showed a unimodal distribution in 
HP-SEC/LALLS. The average molecular weights and 
average degrees of polymerization obtained for 16a,b 
or 17a,b (crude) are significantly higher than those of 
the precursor polymer 14a,b. However, the values of 
the PHEG-spacer conjugates are only apparent because 
the sequence and composition dependence of the 
refractive index increment (dn/dc) [29] due to the 
random nature of the copolymers i difficult o estimate 
and is not accounted for in the data processing. An 
improved estimate of the absolute molecular weight of 
the copolymers might be obtained by measuring the 
apparent molecular weight in different solvents and 
correcting for the dependence on dn/dc of the solvent 
[29]. The separation of crude 17a,b into a high- and 
low-molecular weight fraction is confirmed by the val- 
ues of the apparent average molecular weights of the 
HMW and LMW fractions. 
3.3. Preparation of ADR derivatives 
New derivatives of ADR in which the drug is bound 
either through an acid-labile maleamic acid bond or a 
hydrolytically stable amide bond and which also con- 
tain a thiol functional group, present as the S-acetyl- 
thioacetic acid (SATA) moiety, for coupling with 
carriers have been prepared [ 11,12,20]. The acid-labile 
compound SATA-fl-Ala-fl-methyl,dehydroAsp-ADR 
10 (Fig. 5) and the hydrolytically stable compound 
SATA-fl-Ala-Asp-ADR 9 (Fig. 4) which is used in 
immunoconjugates as a control will be described in 
detail elsewhere [ 20 ]. For coupling to maleimide-acti- 
vated carriers the ADR derivatives are converted to the 
corresponding free thiol by cleavage of the acetyl moi- 
ety in situ with hydroxylamine. 
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Fig. 4. Structure of S2-PHEG-ADR 19a,b prepared from S,-PHEG-OEA-NH2 17a,b, GMBS and SATA-/3-AIa-Asp-ADR 9. 
3.4. Preparation of PHEG-ADR conjugates 
Maleimido groups were introduced onto PHEG con- 
jugates with amine-containing spacers by acylation 
with GMBS [30,31 ] or the water-soluble sulfo deriv- 
ative of SMCC [32]. The polymer-bound maleimido 
groups were reacted with the thiol-containing ADR 
derivatives to allow for the formation of conjugates 
through a thioether bond (Fig. 4 and 5 ). 
The degree of substitution of PHEG with maleimido 
groups and ADR was determined by amino acid anal- 
ysis of y-aminobutyric acid (maleimido groups) and 
/3-Ala (ADR) after hydrolysis of the conjugate 
S2-PHEG-ADR 19a,b in acid (Table 2). The maleim- 
Table 2 
Analytical data of PHEG-bound ADR conjugates prepared from S2-PGA 
Asp-ADR 9 
carrier 14a,b, BOC-OAE spacer 4, GMBS linker and SATA-/3-Ala- 
Conjugate OAE spacer" (mol%) Maleimido linker b ADR c (mol%) Goo (M i cm t DP~nap p"  Mn.appd ( X 10 4) 
( mol% ) 
19a,b S_~-PHEG-ADR 9.1 7.20 (-+0.02) 5.70 (_+0.18) 6700 (_+440) 
batch 1 
19a,b S2-PHEG-ADR 9.1 7.49 (_+0.22) 5.75 (+0.12) 5700 ( _+ 160) 
batch 2 
19a,b S2-PHEG-ADR 9.1 7.43 ( _+ 0.004) 5.83 ( -+ 0.01 ) 6300 ( _+ 100) 
batch 3 c 
133(_+5) 3.11(__+0.12) 
110 (-+1) 2.58(_+0.02) 
80(_+1) 1.88(-+0.02) 
"Relative to Glu as determined by ]H-NMR. 
bCalculated from the amounts of GABA and Glu as determined by amino acid analysis. 
~Calculated from the amounts of/3-Ala and Glu as determined by amino acid analysis. 
dApparent value of reduced conjugate (see section 3) calculated from the amount of Glu as determined by amino acid analysis and the amount 
of thiol groups as determined by DTP assay. 
eUsed for the preparation of radiolabelled immunoconjugate. 
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10 
uble conjugates mediated by the hydrophobicity of the 
(N-maleimidomethyl) cyclohexane moiety. 
3.5. Preparation of radiolabelled immunoconjugates 
of lgM 16.88 and Se-PHEG-ADR 19a, b 
The preparation of the immunoconjugate of IgM 
16.88 and S2-PHEG-ADR 19a,b is similar to that 
described previously [ 10]. The structure of the immu- 
noconjugate is given in Fig. 6. Prior to immunoconju- 
gation IgM 16.88 was labelled with 13JI using the 
iodogen procedure. ~3 q-labelled IgM 16.88 was reacted 
with GMBS to yield a degree of substitution of 18 mol 
of y-maleimidobutyryl (GMB) groups per mol of anti- 
body. The immunoreactivity at this degree of substi- 
tution is fully preserved but is gradually lost by 
increasing the GMB substitution above 20 mol/mol 
(Fig. 7). Conjugate 19a,b was reacted with Cys to 
deactivate remaining polymer-bound maleimido 
groups and subsequently with DTT to reduce the disul- 
fide end groups. Maleimido-activated IgM was then 
added to the thiol-containing conjugate 19a,b allowing 
for the formation of a thioether linkage between poly- 
mer and protein. By using equimolar amounts of pro- 
tein-bound maleimido groups and polymer-bound thiol 
groups virtually complete reaction of both components 
ido and ADR content of various preparations of con- 
jugate indicate almost complete conversion in both 
coupling steps with the polymeric arrier. The molar 
absorbance coefficient of PHEG-bound ADR at 490 
nm (E49o) is significantly reduced as compared to the 
value of free ADR (9800 M ~ cm ~) which may be 
explained by intramolecular o intermolecular interac- 
tion of polymer-bound ADR residues [33]. Because 
19a,b contains fractions with and without disulfide nd 
groups, in unknown relative amounts, the actual values 
of the number-average degree of polymerization (DPn) 
of the thiol-terminated fraction of reduced conjugate 
will be less than the apparent values of DP. calculated 
from the content of thiol groups and the concentration 
of Glu as determined by amino acid analysis 
(Table 2). Due to the unknown polymer composition 
with respect to disulfide/thiol end groups these appar- 
ent DPn values cannot be directly compared with the 
molecular weight data of the polymer precursors dis- 
cussed above. 
The concentrations of PHEG-bound maleimido as 
well as ADR groups in soluble conjugates PHEG-ADR 
20 (Fig. 5) were consistently lower by 50% or more 
in comparison with those obtained for conjugates 
19a,b. Although the origin of these results was not 
investigated the data suggest partial formation of insol- 
 NHONOO1 OH 
! ,OH= | / / 
/ / / / 
/ CO / / C,O j 








PHEG-ADR OH3 / \CONI H 
20 ADR 
Fig. 5. Structure of PHEG-ADR 20 prepared from PHEG-butyI-NH2 18, sulfo-SMCC and SATA-/3-Ala-/3-methyl, dehydroAsp-ADR 10. 
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Fig. 6. Structure of immunoconjugate IgM-PHEG-ADR 22 prepared from lgM and S2-PHEG-ADR 19a,b. 
IgM 
was observed as shown by HP-SEC analysis on Zorbax 
GF-450 (Fig. 8). 
The immunoconjugate was fractionated by gel filtra- 
tion on TSK Fraktogel HW-55S (Fig. 9). The IgM- 
PHEG-ADR conjugate 22 elutes before ither free IgM 
or 19a,b as shown by calibration of the column. This 
result is similar to what is observed for IgM-PGA and 
IgM-PHEG conjugates and is expected on the basis of 
the increased molecular weight [10]. Thus, fractions 
23 and 24 were pooled to yield immunoconjugate with 
a negligible amount of free IgM. The combined frac- 
tions represent 67% recovery of protein. 
IgM-PGA and IgM-PHEG conjugates tudied pre- 
viously have been purified by gel filtration of Fraktogel 
HW-55S [ 10]. Despite careful pooling, free polymers 
were present in the immunoconjugates probably due to 
complex formation between the immunoconjugates 
and free polymers [ 10]. Removal of unreacted 19a,b 
from immunoconjugates r maining after gel filtration 
could be accomplished by anion-exchange chromatog- 
raphy (AEC) on Q-Sepharose Fast Flow using elution 
with a stepwise salt gradient (Fig. 10). Conjugate 
19a,b is almost completely desorbed by elution with 
buffers containing up to 150 mM NaC1. Under these 
conditions IgM 16.88 and 22 remain bound and are 
desorbed by increasing the salt concentration to 250- 
300 mM and 200-250 mM, respectively. By this 
method the remaining amount of 19a,b was removed 
from the immunoconjugate-containing fractions 23 and 
24 from Fraktogel HW-55S (Fig. 11). The immuno- 
conjugate fraction eluted by 250 mM NaCI was con- 
centrated by ultrafiltration and sterilized by filtration 
through a 0.20 tzm filter. The solution thus obtained 
was used for biodistribution experiments. 
The fractions containing immunoconjugate from 
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Fig. 7. Effect of introduction of N-( y-maleimidobutyryloxy ) groups 
onto IgM 16.88 on immunoreactivity. 
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Fig. 8. HP-SEC on Zorbax GF-450 (300× 7.8 mm) in 0.20 M sodium phosphate, pH 7.0 a! a flow rate of 1.0 ml/min. Samples: IgM 16.88, S2- 
PHEG-ADR 19a,b and immunoconjugate 22 prepared from IgM 16.88 and reduced 19a,b (crude reaction mixture). 
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Fig. 9. Preparative SEC on Fraktogel TSK HW-55S (80 × 2.6 cm, 
425 ml) in buffer IV at a flow rate of 40 ml/h. Sample: immunocon- 
jugate 22 prepared from igM 16.88 and reduced S~-PHEG-ADR 
19a,b (crude reaction mixture)• The fractions (5•4 ml each) were 
pooled as indicated by the arrows. 
100]. • S2-PHEG-ADR 
"t ~ -- [] ~ 18.~ "$ 75 ] i  [ ]  F(23+24) ]  F(25-27) 
50 
o 
I o , I 
70 100 150 200 250 300 
mM NaCI 
Fig. 10. Percentage recovery in AEC on Q-Sepharose FF ( 12 × 1.6 
cm, 24 ml) equilibrated in 25 mM Tris. HC1, pH 8.0, buffer contain- 
ing 70 mM NaCI. Samples: S2-PHEG-ADR 19a,b, IgM and immu- 
noconjugate 22 fractions obtained after SEC on Fraktogel HW-55S 
(Fig. 9). The samples were applied in the equilibration buffer and 
stepwise lution was performed with 25 mM Tris. HCI buffer, pH 
8.0 containing 70-300 mM NaCl. 
formed under non-reducing and reducing conditions 
and Western blots on PVDF membranes were prepared 
(Fig. 12). SDS-PAGE under non-reducing conditions 
of fractions ( 23, 25 and 28) obtained after gel filtration 
on Fraktogel HW-55S indicates the presence of immu- 
noconjugate, which hardly penetrates the stacking el. 
IgM is absent in fraction 23 but trace amounts of IgM 
are present in the later fractions. The immunoconjugate 
end product obtained after anion-exchange chromatog- 
raphy of the pooled fractions 23 and 24 on Q-Sepharose 
shows again the absence of IgM. Under reducing 
conditions the immunoconjugate fractions as well as 
• 200 
600" - • A280 
----w--- A490 - 150 
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Fig. 11. Preparative AEC on Q-Sepharose FF ( 12 x 1.6 cm, 24 ml) 
equilibrated in 25 mM Tris. HC1, pH 8.0, buffer containing 70 mM 
NaCI. Sample: combined fractions 23 and 24 containing IgM-PHEG- 
ADR immunoconjugate 22 after SEC on Fraktogel HW-55S (Fig. 
9). The sample was applied in the equilibration buffer and stepwise 
elution was performed with 25 mM Tris. HCI buffer, pH 8.0 con- 
taining 70-300 mM NaCI. 
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Fig. 12. SDS-PAGE under non-reducing (A) and reducing conditions ( B ) of IgM 16.88 (a), IgM-PHEG-ADR 22 after SEC on Fraktogel HW- 
55S, fraction 23 (b), fraction 25 (c) and fraction 28 (d), and 22 after AEC on Q-Sepharose bydesorption with 0.25 M NaCl-containing buffer 
(e). The proteins were stained by Serva Blue G-250 (gels) and DAB after treatment with HRP-linked goat anti-human lgM (Western blots). 
IgM show discrete bands at 86 kDa (heavy chain), 70 
kDa (J chain complex) and 28 kDa (light chain). In 
addition, the immunoconjugates show very diffuse 
bands extending across the gel which represent conju- 
gates of the various chains with PHEG-ADR. The dif- 
fuse character of the bands is due to the polydisperse 
nature of the polymer-protein conjugates with respect 
to degree of substitution by PHEG-ADR and polymer 
molecular weight. Unsubstituted protein chains after 
reduction of IgM-PHEG-ADR are present because 
each mole of IgM has 10 heavy and 10 light chains and 
the average degree of substitution, assuming random 
coupling, is about 14 mol PHEG-ADR per mol of IgM 
or 0.7 mol PHEG-ADR per chain. 
3.6. lmmunoreact iv i ty  o f lgM-PHEG-ADR 22 
Fractions containing IgM-PHEG-ADR 22 were 
assessed for immunoreactivity b  solid-phase EIA 
using HRP-linked goat anti-human IgM (Fig. 13, 
Table 3). To evaluate the titer of the immunoconju- 
gates with respect o CTA-1 binding, the data on the 
active immunoreactivity nvolving assay of immuno- 
conjugate bound to antigen precoated onto the solid 
phase had to be corrected for the altered binding 
between immunoconjugate nd HRP-linked goat anti- 
human IgM. Analysis of the passive immunoreactivity 
by assay of immunoconjugate pr coated onto the solid 
phase shows that binding of HRP-linked goat anti- 
human IgM is slightly weakened in comparison with 
IgM. This may be rationalized by a minor steric hin- 
drance of the binding site of second antibody mediated 
by IgM-bound PHEG-ADR chains. The antigen- 
related titer values show that the immunoreactivity of 
22 is preserved to a large extent compared that of IgM 
16.88. 
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Fig. 13. Titration curves of immunoconjugate (IC) lgM-PHEG- 
ADR 22 fractions determined by solid-phase enzyme immunoassay 
using HRP-linked goat anti-human IgM. Method A (active immu- 
noreactivity), assay of immunoconjugate bound to CTA- 1 precoated 
onto solid-phase; method B (passive immunoreactivity), assay of 
immunoconjugate pr coated onto solid-phase. 
Table 3 
Titers (%) of IgM-PHEG-ADR 22 fractions determined by solid- 
phase nzyme immunoassay using HRP-linked goat anti-human IgM 
Compound Titer(%) 
Method A Method B Antigen-related 
- IgM 100 100 100 
21 GMB-IgM" 67 100 67 
22 lgM-PHEG-ADR crude 20 44 45 
22 IgM-PHEG-ADR after 44 70 63 
SEC b 
22 IgM-PHEG-ADR after 29 54 54 
AEC ~ 
Method A (active immunoreactivity), titer found after assay of 
immunoconjugate bound to CTA-1 precoated onto solid-phase; 
method B (passive immunoreactivity), titer found after assay of 
immunoconjugate pr coated onto solid-phase; antigen-related, titer 
pertinent to antigen binding. 
"18 mol of GMB groups per mol of IgM. 
UFraction 23 obtained after gel filtration on Fraktogel HW-55S ( Fig. 
9). 
Cfraction obtained after AEC on Q-Sepharose Fast Flow by desorp- 
tion with 0.25 M NaCl-containing buffer (Fig. 11 ) and used for 
biodistribution studies. 
3.7. In vitro drug release and cytotoxicity 
The in vitro release rate of ADR from PHEG-ADR 
20 having an acid-labile drug-carrier bond was deter- 
mined by incubation in buffer at two pH values using 
ADR as a control (Fig. 14). The stability of the free 
drug is limited as shown by the time-dependent 
decrease indrug concentration at either pH 6.0 (t~/2 11 
h) or pH 7.5 (ti/2 7 h). Any measured amount of ADR 
released from 20 is thus due to hydrolysis from the 
conjugate and decomposition. The apparent rate of 
release of ADR from 20 is significant only at pH 6.0. 
This is consistent with the acid-labile nature of the 
drug-carrier bond even when the rates of ADR decom- 
position are taken into account. The half-life of ADR 
release due to hydrolysis of 20 is estimated at 8-10 h 
at pH 6.0 and several days at pH 7.5. 
HT-29 human colon adenocarcinoma cells were 
grown in microtitre plates in the presence of PHEG- 
ADR or ADR at pH 6.0 and 7.5 up to day 1, 3 or 5. The 
cells were then washed, incubated in fresh medium at 
pH 7.5 until day 7 and the number of viable cells was 
assessed (Fig. 15). These data show that 20 is more 
effective at pH 6.0 compared with pH 7.5 in accordance 
with the rates of ADR release. 
100 
• PHEG-ADR pH 6.0 I L  
80 _ ~ L . .  O PHEG-ADR pH 7.5 
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Fig. 14. Release of ADR from PHEG-ADR 20 conjugate in sodium 
phosphate buffer, pH 6.0 or 7.5, at 37°C. ADR was used as the 
control. 
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Fig. 15. Inhibition of growth of HT-29 human colon adenocarcinoma 
cells by ADR and PHEG-ADR 20 containing an acid-labile drug- 
carrier bond. 
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Fig. 16. Biodistribntion of 131[ bound to [gM-PHEG-ADR 22 and of 
~25i bound to S2-PHEG-ADR 19a,b in mice carrying subcutaneously 
implanted MRI-H-207 human ovarian tumour xenografts. 
3.8. Biodistribution and tumour uptake of l-~ J l- 
labelled IgM-PHEG-ADR 22, 1251-labelled S2-PHEG- 
ADR 19a, b and 3H-labelled IgM 16.88 
The blood level, tumour uptake and biodistribution 
of 13q-labelled IgM-PHEG-ADR 22, which was co- 
administered with 3H-labelled IgM 16.88, and of I25I- 
labelled S2-PHEG-ADR 19a,b in nude mice carrying 
MRI-H-207 human ovarian tumour xenografts were 
studied at 6, 24 and 48 h after administration (Fig. 16 
and Fig. 17). 125I bound to 19a,b shows a slower blood 
clearance as compared to IgM with minimal uptake in 
organs like liver, spleen and heart. The level of tumour 
uptake of J25I bound to 19a,b is constant over 48 h, 
which means a corresponding increase in the tumour- 
to-blood ratio and is an indication of passive tumour 
targeting. The blood clearance and tumour uptake 
change completely upon administration of immuno- 
conjugate. J3tI bound to 22 shows a significant blood 
level at 6 h but is cleared more rapidly than 3H bound 
to the unmodified antibody with relatively low uptake 
of the label in liver, kidneys and spleen. 13q bound to 
immunoconjugate is taken up appreciably by the turn- 
our at 6 h but disappeared more rapidly than IgM. At 
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Fig. 17. Time dependence of tumour uptake and blood concentration 
of]3q bound to lgM-PHEG-ADR 22, of 3H bound to IgM 16.88 and 
of  125I bound to S2-PHEG-ADR 19a,b in mice carrying subcutane- 
ously implanted MR1-H-207 human ovarian tumour xenografls. 
tissues were detected (data not shown) suggesting the 
almost complete absence of 22. The tumour-to-blood 
ratio of 3H-labelled IgM increases in the period from 6 
to 48 h indicating slow kinetics of the antibody in pen- 
etrating the tumour. The tumour-to-blood ratio of 131I 
bound to 22 shows similar behaviour from 6 to 24 h 
but at 48 h no significant value could be estimated ue 
to the small amount of the label in both the blood and 
the tumour. It is concluded that the residence time of 
the immunoconjugate in the blood is too short to allow 
effective tumour targeting of drug. 
4. Discussion 
In order to deliver a therapeutically effective dose of 
cytostatic drugs to the tumour with IgM 16.88, which 
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is highly susceptible to chemical modification, we 
employed an intermediate drug carrier for which PGA 
and the neutral derivative PHEG were possible candi- 
dates. In order to test he applicability of these polymers 
in targeted rug therapy, immunoconjugates of human 
IgM 16.88 and PGA or PHEG were synthesized and 
purified and subjected to a biodistribution study [ 10]. 
The biodistribution ofeither IgM-PGA or IgM-PHEG 
was identical with that of the IgM proper and we have 
concluded that the polyanion PGA and the uncharged 
derivative PHEG are equally suitable as drug carriers 
in immunoconjugates. Removal of unbound polymers 
from the immunoconjugates by gel filtration was 
incomplete probably due to complex formation. For 
this reason we decided to use PHEG as the carrier 
because purification of immunoconjugates by other 
methods, notably anion- or cation exchange chroma- 
tography, is facilitated by the uncharged character of 
PHEG. 
The release of free drug from carrier-drug conjugates 
by chemical hydrolysis at acid pH, which occurs for 
instance in endosomes and lysosomes of cells, can be 
accomplished byusing the acid-labile cis-aconityl link- 
ers introduced by Shen and Ryser [34]. We have pre- 
pared improved linkers allowing unequivocal binding 
of drug and carrier [ 11,12,20]. The linkers contain a 
drug moiety bound either through an acid-labile or a 
hydrolytically stable bond which is useful for control 
studies as well as an acetyl-protected hiol function for 
conjugation to carriers. The rate of acid-catalyzed 
release of ADR is dependent on the size of the /3- 
substituent a the double bond of the drug linkage (data 
not shown). PHEG-ADR conjugate containing the 
acid-labile ADR derivative shows a significant release 
of ADR upon incubation in buffer solution at pH 6.0. 
Furthermore, ADR is released in cytotoxic amounts 
when HT-29 human colon adenocarcinoma cells are 
cultured in the presence of conjugate at pH 6.0 and to 
a lesser extent also at pH 7.5. In principle, the release 
of drug can be extracellular in the acidic environment 
of the tumour or intracellular, catalyzed by the acidic 
environment of endosomes and lysosomes, after pino- 
cytosis of the conjugate by the cells. The enhanced 
cytotoxicity of PHEG-ADR at pH 6.0 as compared to 
pH 7.5 suggests that at pH 6.0 a major part of the drug 
is released extracellularly. The results indicate that 
extracellular drug release from PHEG-bound ADR in 
an acidic environment could be therapeutically effec- 
tive provided that the residence time of the conjugate 
is sufficiently long. 
In order to bind the ADR derivatives and IgM to 
PHEG independently, the drug carrier having thiol 
groups for coupling with protein was modified by intro- 
duction of amine groups. This was accomplished by a 
multistep rocedure starting from PGA containing thiol 
end groups. The coupling of the ADR derivative with 
PHEG and of IgM with PHEG-ADR were both effected 
by the use of a heterobifunctional coupling agent con- 
taining an activated ester and a maleimido group yield- 
ing an amide bond and a thioether bond, respectively. 
The extent of immunoconjugate formation was 
improved compared with our previous tudy [ 10]. The 
immunoreactivity of the immunoconjugate was almost 
fully preserved indicating that the antigen binding site 
was not denatured or sterically shielded by PHEG- 
ADR to a significant extent. From the data the number 
of drug molecules carried by one molecule of immu- 
noconjugate is estimated at 65. The amount of free 
PHEG-ADR in the immunoconjugate is estimated to 
be low or very low due to the improved method of 
purification. The absence of free IgM allowed us to 
study the biodistribution of the immunoconjugate 
through the 131I label of the antibody. 
To study the biodistribution and tumour uptake of 
IgM-PHEG-ADR and PHEG-ADR we have used the 
MRI-H-207 human ovarian tumour xenograft 
subcutaneously implanted in nude mice [22]. The 
MRI-H-207/nude mice system is an appropriate solid- 
tumour model for ADR-containing conjugates of IgM 
16.88 due to the sensitivity of the tumour to ADR, the 
presence of specific antigen and the extent of vascular- 
ization. The prolonged residence time of PHEG-ADR 
in the tumour and in the circulation enhances the pros- 
pect of PHEG conjugate containing the acid-labile 
ADR derivative for effective therapy as discussed 
above. The residence time of IgM-PHEG-ADR in 
blood as well as in MRI-H-207 human ovarian tumours 
proved to be significantly shorter than that of IgM. 
These results are in contrast with earlier data on the 
biodistribution of an immunoconjugate of IgM 16.88 
and PHEG which was indistinguishable from that of 
unmodified IgM [ 10]. Results very similar to those on 
IgM-PHEG-ADR were obtained with immunoconju- 
gates of IgM and either directly bound ADR or human 
serum albumin-bound ADR (E.S. Bos, unpublished 
data). Apparently, the presence of ADR in the immu- 
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noconjugates alters the phys icochemica l  propert ies in 
such a way that the conjugate becomes  prone to rapid 
c learance with a concomitant  decrease in tumour  
uptake. On the basis of  the present results with the IgM- 
PHEG-ADR immunocon jugate  hav ing a hydrolyt ical ly  
stable drug bond it is conc luded that therapeutical ly 
effect ive drug target ing with immunocon jugates  of
IgM 16.88 and ADR is not practical  in this tumour  
model.  A major  improvement  may be possible by the 
design of  drug carriers which suppress undesired inter- 
act ions of  ADR under  in v ivo condit ions.  
5. Conclusions 
( 1 ) Conjugates  of  PHEG and ADR with either an 
acid- labi le or a hydrolyt ical ly  stable drug-carr ier  bond 
have been prepared by a mult istep procedure. (2)  
Release of  drug in cytotoxic amounts  f rom PHEG-  
bound ADR hav ing an acid- labi le drug-carr ier  bond is 
effected in vitro by using a sl ightly acidic culture 
medium.  (3)  Immunocon jugates  of high purity and 
immunoreact iv i ty  have been obtained f rom IgM 16.88 
and PHEG-ADR.  (4)  Target ing of ADR in a solid 
tumour  model  in mice with an IgM-PHEG-ADR immu-  
noconjugate appears not to be practical probably due 
to biodistr ibut ion effects mediated by the bound drug. 
(5)  PHEG-ADR shows passive target ing in a solid 
tumour  model  in mice due to a pro longed residence 
t ime in the circulation. 
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